SELLAS Life Sciences Group, Inc. Share Price
NASDAQ: SLS | Small CapSELLAS Life Sciences Group, Inc. Stock Performance
Open $11.87 | Prev. Close $11.96 | Circuit Range N/A |
Day Range $10.91 - $11.96 | Year Range $1.39 - $15.86 | Volume 3,29,111 |
Average Traded $11.34 |
SELLAS Life Sciences Group, Inc. Share Price Today
As of 11 August 2026, SELLAS Life Sciences Group, Inc.'s share price is $11.03. The stock opened at $11.87, compared to its previous close of $11.96. During today's trading session, SELLAS Life Sciences Group, Inc.'s share price traded between $10.91 and $11.96, with an average price of $11.44. Over the past 52 weeks, the stock has recorded a high of $15.86 and a low of $1.39. In terms of performance, SELLAS Life Sciences Group, Inc.'s share price has risen by 123.05% over the last six months and is up 475.98% on a year-on-year basis.
SELLAS Life Sciences Group, Inc. Share Price Chart
SELLAS Life Sciences Group, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.20B | PE Ratio (TTM) -44.12 | Dividend Yield N/A |
EPS (TTM) $-0.25 | Revenue (TTM) -$28.27M | Return On Equity (TTM) -37.90% |
Profit Margin 95.01% | Debt to Equity 0.10 | Quarterly Earnings Growth YoY 4.46% |
SELLAS Life Sciences Group, Inc. Quarterly Profit & Loss
All figures in USD
SELLAS Life Sciences Group, Inc. Annual Profit & Loss
All figures in USD
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $9.94 | $12.00 | +20.06% |
Jul 2026 | $14.06 | $9.99 | -32.33% |
Jun 2026 | $9.09 | $14.77 | +58.73% |
May 2026 | $4.93 | $9.30 | +88.74% |
Apr 2026 | $4.28 | $4.93 | +16.82% |
Mar 2026 | $4.67 | $4.22 | -14.66% |
Feb 2026 | $3.69 | $4.95 | +31.17% |
Jan 2026 | $4.39 | $3.77 | -0.40% |
Dec 2025 | $1.58 | $3.79 | +132.92% |
Nov 2025 | $1.84 | $1.63 | -10.47% |
Oct 2025 | $1.61 | $1.81 | +12.73% |
Sep 2025 | $1.91 | $1.61 | -15.93% |
SLS Share Price FAQs
What is SELLAS Life Sciences Group, Inc. share price today?
What is the 52 week high and 52 week low of SELLAS Life Sciences Group, Inc. stock?
What is SLS's market capitalisation today?
What is SLS's net income for the last quarter?
What is the 5 year returns of SLS?
What is the high & low stock price of SLS today?
Can I buy SLS shares in India?